CCX872

News alerts, weekly reports and conference planners

Company:

Amgen

Drug class:

CCR2 receptor antagonist

Related drugs:

‹

BMS-813160 (0)

›

almost2years

FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. (PubMed, J Hepatol)

ETV4 is a prognostic biomarker, and anti-PD-L1 combined with FGFR4 inhibitor BLU-554 or MAPK inhibitor trametinib may be effective strategies to inhibit HCC metastasis.

almost 2 years ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase) • FGF19 (Fibroblast growth factor 19) • FGFR4 (Fibroblast growth factor receptor 4) • HGF (Hepatocyte growth factor) • CCL2 (Chemokine (C-C motif) ligand 2) • CCR2 (C-C Motif Chemokine Receptor 2) • ETV4 (ETS Variant Transcription Factor 4)

PD-L1 expression • FGFR4 expression

Mekinist (trametinib) • fisogatinib (BLU-554) • clodronate disodium • CCX872

3years

[VIRTUAL] FGF19-FGFR4 SIGNALING MEDIATED ETV4 OVEREXPRESSION FACILITATES HEPATOCELLULAR CARCINOMA METASTASIS THROUGH UPREGULATING PD-L1 AND CCL2 (AASLD 2021)

ETV4 facilitated the recruitment and infiltration of TAMs and MDSCs through CCL2-CCR2 pathway, and either knockdown of CCL2 by lentivirus or CCR2 inhibitor CCX872 treatment impaired ETV4-induced TAMs and MDSCs infiltration and HCC metastasis . Either depletion of TAMs by clodronate liposomes or depletion of MDSCs by anti-Gr-1 attenuated ETV4- mediated HCC metastasis... ETV4 is a prognostic biomarker, and targeting this oncogenic pathway may provide a combinational therapeutic strategy to inhibit HCC metastasis .

3 years ago

PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • FGF19 (Fibroblast growth factor 19) • FGFR4 (Fibroblast growth factor receptor 4) • CCL2 (Chemokine (C-C motif) ligand 2)

FGF19 overexpression • FGFR4 expression

fisogatinib (BLU-554) • clodronate disodium • CCX872